Natera shared a post on LinkedIn:
“Join our upcoming webinar, Interpretation, context, and actionability: Navigating low-level ctDNA positives, on Monday, August 3.
Speakers Chirag Shah, and Kevin Manage, plan to:
- Describe the clinical significance of low-level ctDNA positivity and distinguish scenarios where the result may represent true molecular residual disease versus analytical noise.
- Apply a framework for interpreting low-level Signatera results in the context of tumor type, treatment history, and timing of the assay across a pan-tumor patient population.
- Discuss actionability strategies for low-level positive results, including the role of confirmatory testing, imaging correlation, and multidisciplinary tumor board discussion.”
